Log In
Print this Print this

TransCon treprostinil (ACP-009)

  Manage Alerts
Collapse Summary General Information
Company Ascendis Pharma A/S
DescriptionOnce-daily PEG-linked prodrug of treprostinil that uses TransCon prodrug technology for sustained release
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHypertension
Indication DetailsTreat pulmonary arterial hypertension (PAH)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today